Citation: Marco Ferrone, Anna Franzone, Bruno Trimarco, Giovanni Esposito, Plinio Cirillo. Percutaneous Coronary Intervention in a Patient with Acute Thrombosis of Saphenous Vein Graft and Patent Native Coronary Artery: Which is the Vessel to Approach?[J]. AIMS Medical Science, 2015, 2(4): 310-315. doi: 10.3934/medsci.2015.4.310
[1] | Yap CH, Sposato L, Akowuah E, et al. (2009) Contemporary results show repeat coronary artery bypass grafting remains a risk factor for operative mortality. Ann Thorac Surg 87(5): 1386-1391. |
[2] | Sarwar B, Brener SJ (2014) Saphenous vein graft interventions. Curr Treat Options Cardiovasc Med 16(5): 301. |
[3] | Brilakis ES, Lichtenwalter C, Abdel-karim AR, et al. (2011) Continued benefit from paclitaxel-eluting compared with bare-metal stent implantation in saphenous vein graft lesions during long-term follow-up of the SOS (Stenting of Saphenous Vein Grafts) trial. JACC Cardiovasc Interv 4(2): 176-182. |
[4] | Xanthopoulou I, Davlouros P, Tsigkas G, et al. (2011) Long-term clinical outcome after percutaneous coronary intervention in grafts vs native vessels in patients with previous coronary artery bypass grafting. Can J Cardiol 27(6): 716-724. |
[5] | Hoffmann R, Nitendo G, Deserno V, et al. (2010) Follow-up results after interventional treatment of infarct-related saphenous vein graft occlusion. Coron Artery Dis 21(2): 61-64. |
[6] | Yeh RW, Sidney S, Chandra M, et al. (2010) Population trends in the incidence and outcomes of acute myocardial infarction. N Engl J Med 362(23): 2155-2165. |
[7] | Abdel-Karim AR, Banerjee S, Brilakis ES (2010) Percutaneous intervention of acutely occluded saphenous vein grafts: contemporary techniques and outcomes. J Invasive Cardiol 22(6): 253-257. |
[8] | Gaglia MA, Torguson R, Xue Z, et al. (2011) Outcomes of patients with acute myocardial infarction from a saphenous vein graft culprit undergoing percutaneous coronary intervention. Catheter Cardiovasc Interv 78(1): 23-29. |
[9] | Mehilli J, Pache J, Abdel-Wahab M, et al. (2011) Drug-eluting versus bare-metal stents in saphenous vein graft lesions (ISAR-CABG): a randomised controlled superiority trial. Lancet 378(9796): 1071-1078. |
[10] | Vermeersch P, Agostoni P, Verheye S, et al. (2007) Increased late mortality after sirolimus-eluting stents versus bare-metal stents in diseased saphenous vein grafts: results from the randomized DELAYED RRISC Trial. J Am Coll Cardiol 50(3): 261-267. |
[11] | Costopoulos C, Latib A, Naganuma T, et al. (2013) Comparison of first- and second-generation drug-eluting stents in saphenous vein grafts used as aorto-coronary conduits. Am J Cardiol 112(3): 318-322. |
[12] | Taniwaki M, Räber L, Magro M, et al. (2014) Long-term comparison of everolimus-eluting stents with sirolimus- and paclitaxel-eluting stents for percutaneous coronary intervention of saphenous vein grafts. EuroIntervention 9(12): 1432-1434. |
[13] | Kitabata H, Loh JP, Pendyala LK, et al. (2013) Two-year follow-up of outcomes of second-generation everolimus-eluting stents versus first-generation drug-eluting stents for stenosis of saphenous vein grafts used as aortocoronary conduits. Am J Cardiol 112(1): 61-67. |